Dilgem (4mg) 20 Tablets

Glimepiride is an insulin secretagogue, this drug is only effective in patients with residual pancreatic beta-cell activity. Glimepiride acts at ATP-dependent potassium channels on the cell membrane of pancreatic beta cells, resulting in iatrogenic depolarization by prevention of potassium from cell excitation. This depolarization activates voltage-dependent calcium channels on the cell membrane, resulting in an increase in intracellular calcium levels and increase in subsequent exocytosis of insulin into the bloodstream. Insulin now acts on cell membrane receptors and triggers GLUT-4 expression and glucose movement into the cell, this mechanism lowers blood glucose levels. Glimepiride interacts with Epac3, a nucleotide exchanger that works by mediating the exocytosis of insulin granules. Glimepiride is an oral blood-glucose-lowering drug of the sulfonylurea class. It can be used concomitantly with other drugs for glycemic control like metformin and also along with insulin. But its use along with insulin can cause hypoglycemia( low level of glucose). Used as an adjunct to diet and exercise to lower the blood glucose (sugar) in patients with noninsulin-dependent (Type 2) diabetes mellitus whose hyperglycemia (high level of glucose) cannot be controlled by diet and exercise alone.

Glimepiride

Tablet

Diabetes Type 2

Dose must be taken according to the doctor’s advice only; doses given below are suggested as supportive literature for better understanding in some areas of requirements. Adult dose: Dose must be adjusted after testing the level of fasting blood glucose in the patient. Usual Starting Dose is 1-2 mg once daily. The maximum starting dose should be no more than 2 mg. The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. Patients with renal Insufficiency must be given 1mg as daily dose.

Overdosage of this drug can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger.

If you miss any dose then take the dose as soon as you remember, but if it's the time for the next dose then do not double the dose.

Take it orally according to your doctor’s advice.

This drug is contraindicated in patients with known hypersensitivity to the Glimepiride and in patients with diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. It must not be recommended for use in pregnancy or nursing mothers. Data are insufficient to recommend pediatric use of this drug.

Dizziness Asthenia(extreme fatigue) Headache Nausea Vomiting Gastrointestinal pain Diarrhea Urticaria Photosensitivity reactions Hyponatremia Syndrome of inappropriate antidiuretic hormone (SIADH) secretion Allergic vasculitis (inflammation of blood vessels) Leukopenia Agranulocytosis Thrombocytopenia Hemolytic anemia Aplastic anemia Pancytopenia have also been reported with sulfonylureas Including Econid

Administration of oral hypoglycemic drugs has been reported to be linked with increased cardiovascular mortality (deaths due to heart disease) as compared to treatment with diet alone or diet plus insulin. The patient should be informed of the potential risks and advantages of Glimepiride use.

Diet management along with this medicine, indicated by your doctor, is necessary for your health. Monitor your carbohydrate intake specifically.

Do not store above 30°C. Protect from sunlight and moisture.